Benidipine
From Wikipedia, the free encyclopedia
![]() |
|
![]() |
|
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Oral |
ATC code | C08CA15 (WHO) |
Identifiers | |
|
|
CAS Number | 105979-17-7 ![]() |
PubChem (CID) | 656668 |
ChemSpider | 571013 ![]() |
UNII | 4G9T91JS7E ![]() |
ChEMBL | CHEMBL2218858 ![]() |
Chemical and physical data | |
Formula | C28H31N3O6 |
Molar mass | 505.562 |
3D model (Jmol) | Interactive image |
|
|
|
|
![]() ![]() |
Benidipine (INN), also known as Benidipinum or benidipine hydrochloride, is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension). It is a triple L-, T-, and N-type calcium channel blocker. It is reno- and cardioprotective.
Contents
Dosing[edit]
Benidipine is dosed as 2–8 mg once daily.[1]
Availability[edit]
Benidipine is sold as Coniel by Kyowa Hakko Kogyo.
Benidipine is only licensed for use in Japan and selected Southeast Asian countries, where it is sold as 4 mg tablets.
Mechanism[edit]
Benidipine is a calcium channel blocker.
Benidipine has additionally been found to act as an antagonist of the mineralocorticoid receptor, or as an antimineralocorticoid.[2]
References[edit]
- ^ Hi-Eisai Pharmaceutical, Inc. "Coniel (benidipine) package insert (Philippines)". MIMS Philippines. CMPMedica. Retrieved 2008-03-31.
- ^ Luther, James M. (2014). "Is there a new dawn for selective mineralocorticoid receptor antagonism?". Current Opinion in Nephrology and Hypertension. 23 (5): 456–461. doi:10.1097/MNH.0000000000000051. ISSN 1062-4821.